SymThera Ltd is a biopharmaceutical start-up with a drug discovery and development program for treating the autoimmune diseases, Multiple Sclerosis, Rheumatoid Arthritis, Crohn's disease and Psoriasis. There are no effective drugs for these and related inflammatory diseases. Available medicines are restricted to disease sub-types, are palliative at their best and cause severe side effects.


SymThera's drug leads, biological peptides, address the immediate shortcomings of existing medication in the following ways:

Protein derivatives - low toxicity, natural products

High specificity therapeutics - minimal side effects

Immune modulators – inducers of immune tolerance 


SymThera combines scientific insight with proprietary technology to rationally design drug leads with high target specificity and enhanced therapeutic potential.